Indication |
For use, as an adjunct, in the treatment of pulmonary tuberculosis. |
Pharmacodynamics |
Ethambutol is an oral chemotherapeutic agent which is
specifically effective against actively growing microorganisms of the
genus Mycobacterium, including M. tuberculosis. Ethambutol inhibits RNA synthesis and decreases tubercle bacilli replication. Nearly all strains of M. tuberculosis and M. kansasii as well as a number of strains of MAC are sensitive to ethambutol. |
Mechanism of action |
Ethambutol inhibits arabinosyl transferases which is involved in
cell wall biosynthesis. By inhibiting this enzyme, the bacterial cell
wall complex production is inhibited. This leads to an increase in cell
wall permeability. |
Absorption |
About 75% to 80% of an orally administered dose of ethambutol is absorbed from the gastrointestinal tract. |
Volume of distribution |
Not Available |
Protein binding |
20-30% |
Metabolism |
Hepatic. Up to 15% of administered drug is metabolized to
inactive metabolites. The main path of metabolism appears to be an
initial oxidation of the alcohol to an aldehydic intermediate, followed
by conversion to a dicarboxylic acid. |
Route of elimination |
During the 24-hour period following oral administration of
ethambutol hydrochloride approximately 50 percent of the initial dose is
excreted unchanged in the urine, while an additional 8 to 15 percent
appears in the form of metabolites. From 20 to 22 percent of the initial
dose is excreted in the feces as unchanged drug. |
Half life |
In patients with normal renal function, 3 to 4 hours. In patients with impaired renal function, up to 8 hours. |
Clearance |
Not Available |
Toxicity |
The most commonly recognized toxic effect of ethambutol is optic
neuropathy, which generally is considered uncommon and reversible in
medical literature. Other side effects that have been observed are
pruritus, joint pain, gastrointestinal upset, abdominal pain, malaise,
headache, dizziness, mental confusion, disorientation, and possible
hallucinations. |